Hippo Pathway

Overview

Why do organs stop growing at the right size? Why does a liver regenerate to a species-specific volume and not beyond? How do cells know they are crowded? The Hippo pathway is a major part of the answer. First worked out in Drosophila — where loss-of-function mutations caused overgrown tissues resembling a hippopotamus — the pathway has been mapped onto mammalian biology and is now recognized as a central regulator of proliferation, apoptosis, and stem cell self-renewal.

Its centerpieces are two transcriptional co-activators, YAP (yes-associated protein) and its paralog TAZ (WWTR1). When Hippo signaling is active, YAP and TAZ are phosphorylated and sequestered in the cytoplasm or degraded. When Hippo signaling is inactive, they enter the nucleus and drive programs of growth and survival.

How It Works

The Core Kinase Cascade

• MST1/MST2 (mammalian orthologs of fly Hippo) are Ste20-family kinases activated by upstream signals and scaffolded by SAV1 (Salvador).
• MST1/2 phosphorylate and activate LATS1/LATS2 (large tumor suppressor kinases), assisted by MOB1.
• LATS1/2 phosphorylate YAP (at Ser127 and others) and TAZ, creating 14-3-3 binding sites that trap them in the cytoplasm and phospho-degrons that drive their ubiquitination.

When the cascade is off, YAP/TAZ enter the nucleus and partner with the TEAD family of transcription factors to activate genes such as CTGF, CYR61, AXL, and ANKRD1 — a pro-proliferative, anti-apoptotic, pro-migratory program.

Upstream Inputs

Unlike most pathways with a clean ligand-receptor front end, Hippo integrates many cues:

• Cell-cell contact: cadherins, the apical Crumbs complex, and tight junctions activate the kinase core as density rises (contact inhibition).
• Mechanical cues: stiff substrates, cytoskeletal tension, and cell spreading inactivate LATS1/2 and release YAP/TAZ — making Hippo the best-characterized mechanotransduction pathway in the cell.
• GPCR ligands: LPA, S1P, thrombin, and estrogens activate YAP via Gα12/13 and Rho GTPases through GPCR signaling; conversely, Gαs-coupled receptors inhibit YAP.
• Metabolic state: energy stress via AMPK, glucose availability, and cholesterol sensing modulate YAP activity, linking Hippo to mTOR.

Crosstalk

YAP/TAZ cooperate with Wnt, Notch, TGF-β, and MAPK/ERK signaling. For example, cytoplasmic YAP can bind β-catenin and restrain Wnt output, while nuclear YAP/TEAD synergizes with Smads to drive fibrosis programs.

Biological Roles

Organ Size and Regeneration

Liver-specific deletion of MST1/2 or sustained YAP activation produces massively enlarged livers that revert when signaling is normalized. Controlled, transient YAP activity appears to be required for normal liver, heart, and intestinal regeneration — making the pathway a regenerative medicine target.

Stem Cell Maintenance

YAP/TAZ support stemness in intestinal crypts, skin, and mammary tissue. Their activity is tightly tuned; too much drives dysplasia, too little starves stem cell niches. Mechanical cues from the extracellular matrix and from actin cytoskeletal tension feed directly into this decision.

Cancer and Fibrosis

Hippo is among the most frequently dysregulated tumor suppressor pathways in human cancer. NF2 (merlin) loss in mesothelioma, LATS mutations, YAP/TAZ gene amplification, and YAP-TFE3 fusions all drive disease. Activated YAP/TAZ in cancer-associated fibroblasts also stiffens the tumor stroma, reinforcing mechanical YAP activation in cancer cells — a vicious cycle. In fibrotic diseases (lung, liver, kidney), YAP/TAZ cooperate with TGF-β to drive myofibroblast phenotypes.

Relevance to Peptides

Several peptide angles exist:

• GPCR peptide ligands that act through Gα12/13 — including components of the renin-angiotensin system and some chemokines — are strong YAP activators. This connects cardiovascular peptide biology to tissue growth control.
• Peptide disruptors of YAP-TEAD interactions: because YAP and TEAD interact over a broad interface, peptide inhibitors (stapled peptides, cyclic peptides from phage display) have emerged as promising chemical biology tools and drug leads.
• Mechanotransduction in peptide delivery: because cellular mechanics affect endocytosis and receptor recycling, delivery vehicles for peptide drugs often interact with the same cytoskeletal machinery that governs Hippo.

Therapeutic Implications

Direct small-molecule inhibitors of TEAD palmitoylation (the lipid site required for YAP-TEAD association) have entered clinical trials for NF2-deficient mesothelioma. Efforts to activate YAP transiently for wound healing and cardiac regeneration are also underway. Peptide inhibitors that mimic VGLL proteins to compete with YAP for TEAD binding are a promising parallel track, and combinations with PI3K/Akt or mTOR blockers are being tested.

Current Questions

How context (tissue type, stiffness, coexisting mutations) determines whether YAP/TAZ activation drives regeneration versus cancer, and how to deliver selective inhibitors to tumor cells without impairing normal renewal, are open. The interplay between Hippo, autophagy, and apoptosis at the single-cell level is a fast-moving field with implications across oncology, regenerative medicine, and peptide therapeutics.